Is Personal Experience Essential for Effective Psychedelic Therapists?: The Challenges of Small, Accumulating Therapist Effects.
Mitch Earleywine, Samantha G. Gomez
Psychedelic Medicine September 4, 2024 DOI: 10.1089/psymed.2023.0054 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Randomized Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Therapist competence Therapist skills Professional training Therapeutic competence Clinical skills Therapist expertise Therapist personal experience Therapist self-experience Therapist's lived experience Patient outcomes Treatment success Therapeutic results Patient success |
| Citations | 5 |
| Key points | Argues that personal psychedelic experience (PEP) likely benefits PAT therapists and is valued by clients, but legal prohibitions block trainee access. A definitive randomized trial would need far more resources than almost any prior PAT or therapist-effects study; power analyses suggest 80-160 participants, ideally 80 therapists treating 30 clients each. Underpowered designs risk misinterpreting null results as evidence that PEP provides no advantage. The authors propose that permitting trainee access would likely create more positives than harms. |
Abstract
Many authors assert that those who provide psychedelic-assisted therapy (PAT) likely benefit from having personal experiences with psychedelics (PEP) as part of their training. Meta-analytic results confirm advantages of experiential learning in other forms of training as well. Potential PAT clients, especially those who identify as members of underrepresented groups, report that PEP is important to them in their choice of guides. Establishing PAT's efficacy will require more trained professionals for generating appropriately powered clinical trials. Despite these rationales for PEP for trainees, prevalent legal prohibitions limit access to psychedelics, preventing trainees from obtaining experiences that many potential clients deem important. A randomized clinical trial comparing outcomes in those trained with PEP to those trained without the experience has intuitive appeal. Nevertheless, a close look at challenges related to design suggests that a definitive experiment would require more resources than almost every previous study of PAT or therapist effects. (Based on effect size estimates from other therapist effects, power analyses reveal that an experiment with 80-160 participants could offer meaningful data. An ideal design would require 80 therapists treating 30 clients each.) Underpowered designs, however, could lead to serious misinterpretations that would suggest that PEP fails to provide advantages. Given the severity of symptoms targeted by PAT, the current need for treatment providers (especially members of underrepresented groups), the rarity of serious negative consequences in supervised drug administration trials, and the low potential for PEP-induced symptoms of dependence, permitting trainees access likely would create more positives than harms.
Citations in the library
Cited by 6
- Expert recommendations for Germany’s integration of psychedelic-assisted therapy BMC Medical Education October 24, 2024
- Anthropology of Psychedelics Anthropology of Consciousness April 20, 2025
- Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians. Therapeutic Advances in Psychopharmacology 2026
- A Perspective for Enhancing the Supervision of Psychedelic-Assisted Therapy: Motivational-Interviewing-Enhanced Integration Supervision (MIE-IS) Psychoactives June 25, 2025
- Ethics of psychedelics in clinical research: a state-of-the-field review JME Practical Bioethics October 9, 2026
and 1 more in the library
Cites 18
- Human hallucinogen research: guidelines for safety. Journal of Psychopharmacology July 1, 2008
- Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences Journal of Psychopharmacology August 31, 2016
- The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act Neuropharmacology June 5, 2018
- Psychedelics and Mental Health: A Population Study PLoS One August 19, 2013
- Adverse effects of psychedelics: From anecdotes and misinformation to systematic science. Journal of Psychopharmacology February 2, 2022
and 13 more in the library